Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
NCT07228702Phase 1Enrolling by invitation
- Sponsor
- Vancouver Coastal Health
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Mycobacteriophage Muddy_HRMN0052 in Nontuberculous Mycobacterial Lung Disease (NTM-LD) and Mycobacterium abscessus infection, sponsored by Vancouver Coastal Health. Primary endpoint: Microbiologic Response at 2 years. Started Jan 2026; status: enrolling by invitation.
02
Drugs
Mycobacteriophage Muddy_HRMN0052
03
Conditions
Nontuberculous Mycobacterial Lung Disease (NTM-LD)Mycobacterium abscessus infection
Beyond the preview
Go deeper on NCT07228702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228702.